PIM3 and hepatocellular carcinoma: PIM3 levels were also increased to varying degrees by rapamycin treatment in the hepatocellular carcinoma (HCC) lines JHH-4, Hep-G2 and JHH-6 (Fig. 2c–e), and the breast cancer cell lines MDA-MB-453 and MDA-MB-468 (Fig. 2f,g).